[1]邢文静a,卢相琴,齐敬聪b,等.血清高尔基体糖蛋白73与MIF水平联合检测对原发性肝癌的诊断和预后价值研究[J].现代检验医学杂志,2022,37(02):66-70.[doi:10.3969/j.issn.1671-7414.2022.02.014]
　XING Wen-jinga,LU Xiang-qin,QI Jing-congb,et al.Study on the Diagnostic and Prognostic Value of Serum Golgiglycoprotein 73 Combined with MIF Level in Primary Liver Cancer[J].Journal of Modern Laboratory Medicine,2022,37(02):66-70.[doi:10.3969/j.issn.1671-7414.2022.02.014]
点击复制

血清高尔基体糖蛋白73与MIF水平联合检测对原发性肝癌的诊断和预后价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年02期
页码:
66-70
栏目:
论　著
出版日期:
2022-03-15

文章信息/Info

Title:
Study on the Diagnostic and Prognostic Value of Serum Golgiglycoprotein 73 Combined with MIF Level in Primary Liver Cancer
文章编号:
1671-7414（2022）02-066-06
作者:
邢文静1a; 卢相琴2; 齐敬聪1b; 段林梅1a
（1. 张家口市传染病医院a. 检验科；b. 肝病科, 河北张家口 075000；2. 张家口市第一医院检验科，河北张家口 075000 ）
Author(s):
XING Wen-jing1a; LU Xiang-qin2 ; QI Jing-cong1b; DUAN Lin-mei1a
（1a. Department of Clinical Laboratory ; 1b.Department of Liver Disease, Zhangjiakou Infectious Disease Hospital,Hebei Zhangjiakou 075000, China; 2. Department of Clinical Laboratory, the First Hospital of Zhangjiakou，Hebei Zhangjiakou 075000，China）
关键词:
高尔基体糖蛋白73; 巨噬细胞移动抑制因子; 原发性肝癌
分类号:
R735.7；R30.43
DOI:
10.3969/j.issn.1671-7414.2022.02.014
文献标志码:
A
摘要:
目的　探讨联合高尔基体糖蛋白73（golg glycoprotein, GP73），巨噬细胞移动抑制因子（migration inhibitory factor, MIF）诊断原发性肝癌(primary liver cancer, PLC) 以及预测原发性肝癌患者预后的价值。方法　选择2016 年1 月~2020 年1 月张家口市传染病医院肝病科收治的137 例原发性肝癌患者（肝癌组）、101 例肝良性肿瘤患者（肝良性肿瘤组）和109 例于门诊体检的健康志愿者（健康对照组）。检测血清GP73，MIF 水平，比较原发性肝癌不同病理特征和预后间血清GP73 和MIF 水平差异。Kaplan-Meier 法绘制不同GP73 和MIF 水平原发性肝癌患者生存曲线，受试者工作特征曲线（ROC）分析GP73 和MIF 诊断原发性肝癌以及预测原发性肝癌患者预后的价值。结果　肝癌组血清GP73（68.53±21.35 μg/L），MIF（123.35±20.48 pg/ml ）水平高于肝良性肿瘤组（13.42±6.52μg/L，43.02±7.61pg/ml）和健康对照组（13.13±6.25 μg/L，42.12±7.58 pg/ml），差异有统计学意义（t=25.081~39.309，均P ＜ 0.05）。TNM分期Ⅲ～Ⅳ期血清GP73（75.11±7.16μg/L），MIF（127.62±10.82 pg/ml）水平高于Ⅰ ~ Ⅱ期（54.15±10.42μg/L，114.02±12.05 pg/ml），差异有统计学意义（t=13.696，6.586，均P=0.000），死亡患者血清GP73（78.32±6.06 μg/L），MIF （130.12±6.03 pg/ml）水平高于存活患者（58.00±10.03μg/L，116.07±12.94 pg/ml），差异有统计学意义（t=14.467，8.239，均P ＜ 0.05）。 GP73 ≥ 68.53μg/L 组，MIF ≥ 123.35 pg/ml 组患者生存率
[34.29%（24/70），33.80%（24/71）]低于GP73 ＜ 68.53μg/L 组的62.69%（42/67） 和MIF ＜ 123.35 pg/ml 组的63.64%（42/66）（Log-Rankχ2=10.270，11.450，均P ＜ 0.05）。GP73，MIF 联合检测诊断原发性肝癌、预测原发性肝癌患者预后的曲线下面积分别为0.872，0.868，高于单独指标检测（均P ＜ 0.05）。结论　原发性肝癌患者血清GP73，MIF 水平均明显增高，且与TNM 分期和患者预后均存在一定关系，GP73，MIF 联合检测可为原发性肝癌诊断和预后预测提供参考。
Abstract:
Objective　 To investigate the value of combined with golgiglycoprotein73 (GP73) and macrophage migration inhibitory factor (MIF) in the diagnosis and prediction of prognosis of patients with primary liver cancer. Methods　From January 2016 to January 2020, 137 patients with primary liver cancer (liver cancer group) from Department of Liver Diseases, Zhangjiakou Infectious Diseases Hospital, 101 patients with benign liver tumor (benign liver tumor group) and 109 healthy volunteers who underwent physical examination in outpatient department (healthy control group) were selected. The levels of serum GP73 and MIF were detected, and the differences in coagulation four indices，serum GP73 and MIF levels were compared among different pathological features and prognosis of primary liver cancer. Kaplan-Meier method was used to draw survival curves of primary liver cancer patients with different GP73 and MIF levels. Receiver operating characteristic curve (ROC) was used to analyze the value of GP73 and MIF in the diagnosis and prediction of prognosis of patients with primary hepatocellular carcinoma. Results　The levels of serum GP73（68.53±21.35 μg/L）and MIF（123.35±20.48 pg/ml） in HCC group were higher than those in benign liver tumor group（13.42±6.52μg/L, 43.02±7.61pg/ml） and healthy control group(13.13±6.25μg/L, 42.12±7.58pg/ml) , the differences were statistically significant(t=25.081~39.309，all P<0.05). The levels of GP73（75.11±7.16μg/L） and MIF (127.62±10.82 pg/ml）in patients with TNM Ⅲ ~ Ⅳ stage were higher than those in patients with Ⅰ ～ Ⅱ stage（54.15±10.42μg/L，114.02±12.05pg/ml）, the differnces were statistically significant （t=13.696，6.586，all P<0.000）, and levels of GP73（78.32±6.06 μg/L） and MIF (130.12±6.03 pg/ml）patients with death were higher than those patients with survival （58.00±10.03μg/L,116.07±12.94pg/ml）, the differnces were statistically significant(t=14.467，8.239，all P<0.05). The survival rate of patients in GP73 ≥ 68.53μg/L group and MIF ≥ 123.35 pg/ml group was 34.29% (24/70) and 33.80% (24/71) respectively. That was lower than that of 62.69% (42/67) and 63.64% (42/66) in GP73 < 68.53μg/L group and MIF < 123.35 pg/ml group (log-RANKχ2 =10.270, 11.450, all P < 0.05).The area under the curve by combined with GP73 and MIF in the diagnosis and prediction of prognosis of patients with primary liver cancer were 0.872， 0.868, respectively, which were higher than those of the single index (P<0.05). Conclusion　The levels of serum GP73 and MIF in patients with primary liver cancer are significantly increased, and there is a certain correlation with TNM stage and prognosis. The combination of GP73 and MIF can provide reference for diagnosis and prediction of prognosis of primary liver cancer.

参考文献/References:

[1] HARTKE J, JOHNSON M, GHABRIL M. The diagnosis and treatment of hepatocellular carcinoma[J]. Seminars in Diagnostic Pathology, 2017, 34(2): 153-159.
[2] 中华预防医学会肝胆胰疾病预防与控制专业委员 会, 中国研究型医院学会肝病专业委员会, 中华医 学会肝病学分会, 等. 原发性肝癌的分层筛查与监 测指南(2020 版) [J] . 中华肿瘤杂志, 2021, 43(1): 60-77． Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association, Committee of Hepatology of Chinese Research Hospital Association, Society of Hepatology of Chinese Medical Association, et al. Guideline for stratified screening and surveillance of primary liver cancer(2020 Edition) [J]. Chinese Journal of Oncology,2021,43(1):60-77.
[3] 周伟平, 杨远. 提高原发性肝癌的规范化诊断水平 [J]. 中华消化外科杂志, 2018, 17(5):430-432. ZHOU We i p i n g , YANG Yu a n . I m p r o v i n g the standardized diagnosis level for primary liver cancer [J]. Chinese Journal of Digestive Surgery,2018,17(5):430-432.
[4] 鲁凤民, 张芸．血清高尔基体糖蛋白73 在肝硬化 诊断中的应用及其相关机制[J]．中华肝脏病杂志, 2018, 26（5）：321-324． LU Fengmin,ZHANG Yun. Diagnostic application of serum GP73 and the relevant mechanism in the diagnosis of liver cirrhosis [J]. Chinese Journal of Hepatology,2018,26(5):321-324.
[5] KOH H M, KIM D C. Prognostic significance of macrophage migration inhibitory factor expression in cancer patients: A systematic review and meta-analysis. Medicine (Baltimore), 2020, 99(32):e21575.
[6] 中华人民共和国卫生和计划生育委员会医政医管 局. 原发性肝癌诊疗规范(2017 年版)[J]．中华肝脏 病杂志,2017,25(12):886-895. Bureau of Medical Administration, National Health and Family Planning Comission of the People’s Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (V2017)[J].Chinese Journal of Hepatology,2017,25(12):886-895.
[7] 沈海涛, 焦荣红, 陆志成, 等．原发性肝癌患者外周 血CD39+,CD73+ 调节性T 细胞和自然杀伤(NK) 细 胞的表达及其与肝损伤的相关性[J]．现代检验医学 杂志,2019,34(1):10-13. SHEN Haitao,JIAO Ronghong,LU Zhicheng,et al. Correlation between the expression of peripheral blood CD39+ and CD73+ in regulatory T cells and nature kill cell in patients with hepatocellular carcinoma and liver injury [J]. Journal of Modern Laboratory Medicine,2019,34(1):10-13.
[8] 刘兴晖, 宋惠, 徐莉敏, 等．乙型肝炎病毒对高尔基 体糖蛋白-73 表达的影响研究[J]．中国卫生检验杂 志,2017,27(1):49-50,126. LIU Xinghui,SONG Hui,XU Limin,et al. Study on the effect of hepatitis B virus on the expression of Golgi protein 73 [J]. Chinese Journal of Health Laboratory Technology,2017,27(1):49-50,126.
[9] 左凌云, 张斌, 钱晶晶, 等. 自身免疫性肝炎患者血 清高尔基体糖蛋白73 的变化特征[J]. 肝脏, 2019, 24(9):1053-1054. ZUO Lingyun,ZHANG Bin,QIAN Jingjing,et al.Changes of serum Golgi protein 73 in patients with autoimmune hepatitis[J]. Chinese Hepatology, 2019,24(9):1053-1054.
[10] WEI Meijuan, XU Zhengju, PAN Xingnan, et al. Serum GP73 - an additional biochemical marker for liver inflammation in chronic HBV infected patients with normal or slightly raised ALT[J]. Sci Rep, 2019, 9(1):1170.
[11] 聂东雷, 陈亚晗. 血清高尔基体蛋白73 与肝脏疾病 研究进展[J]. 中华实用诊断与治疗杂志, 2016, 30 (8):735-737. NIE Donglei,CHEN Yahan. Progress of the correlation between serum Golgi protein 73 and liver diseases [J]. Journal of Chinese Practical Diagnosis and Therapy, 2016,30(8):735-737.
[12] KE Mengyun, WU Xiaoning, ZHANG Yao, et al. Serum GP73 predicts posthepatectomy outcomes in patients with hepatocellular carcinoma[J]. Journal of Translational Medicine, 2019, 17(1): 140.
[13] WANG Leijie, YAO Mingjie, LIU Shudong, et al. Serum golgi protein 73 as a potential biomarker for hepatic necroinflammation in population with nonalcoholic steatohepatitis[J]. Disease Markers, 2020, 2020: 6036904.
[14] ZHANG Xuewu, ZHU Chengliang, WANG Tianci, et al. GP73 represses host innate immune response to promote virus replication by facilitating MAVS and TRAF6 degradation [J].PLoS Pathog, 2017, 13(4):e1006321.
[15] CALANDRA T, BUCALA R. Macrophage migration inhibitory factor (MIF): A glucocorticoid counterregulator within the immune system[J]. Critical Reviews in Immunology, 2017, 37(2/6):359-370.
[16] FARAG A, HAMMAM M A, HABIB M S, et al. Macrophage migration inhibitory factor as an incriminating agent in vitiligo[J]. Anais Brasileiros de Dermatologia, 2018, 93(2): 191-196.
[17] KIM K W, KIM H R. Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis[J]. the Korean Journal of Internal Medicine, 2016, 31(4): 634-642.
[18] VUKI?EVI? D, ROV?ANIN B, GOP?EVI? K, et al. The role of MIF in hepatic function, oxidative stress, and inflammation in thioacetamide-induced liver injury in mice: protective effects of betaine[J]. Current Medicinal Chemistry, 2021, 28(16): 3249-3268.
[19] SUBBANNAYYA T, LEAL-ROJAS P, BARBHUIYA M A, et al. Macrophage migration inhibitory factor -a therapeutic target in gallbladder cancer[J]. BMC Cancer, 2015, 15: 843.
[20] YUAN T, TANG C, CHEN M, et al. Influence of the human MIF promoter polymorphism on hepatocellular carcinoma prognosis[J]. Genetics and Molecular Research : GMR, 2013, 12(4): 6629-6635.
[21] 马晓飞, 林泽伟．原发性肝癌患者血清MIF, VEGF 的表达及临床意义分析[J]. 肝胆外科杂志, 2020, 28 (3):185-189. MA Xiaofei,LIN Zewei. Expression and clinical significance of serum MIF and VEGF in patients with primary liver cancer[J]. Journal of Hepatobiliary Surgery ,2020,28(3):185-189.
[22] 魏敏, 曹莉婷, 卢利霞, 等．MIF 与JNK1 在原发性 肝细胞癌中的表达及相关性研究[J]．胃肠病学和肝 病学杂志,2020,29(6):641-646. WEI Min,CAO Liting,LU Lixia,et al. The expression and correlation between MIF and JNK1 in primary hepatocellular car-cinoma[J]. Chinese Journal of Gastroenterology and Hepatology,2020,29(6):641-646.

相似文献/References:

[1]那将超,狄长安.甲状腺乳头状癌患者术后血清MMIF 和IL-6 表达水平与甲状旁腺功能减退持续时间的相关性研究[J].现代检验医学杂志,2023,38(01):191.[doi:10.3969/j.issn.1671-7414.2023.01.036]
　NA Jiang-chao,DI Chang-an.Correlation between Postoperative Serum MMIF and IL-6 Expression Levels and Duration of Hypoparathyroidism in Patients with Papillary Thyroid Cancer[J].Journal of Modern Laboratory Medicine,2023,38(02):191.[doi:10.3969/j.issn.1671-7414.2023.01.036]

备注/Memo

备注/Memo:
基金项目：河北省医学科学研究课题计划20201605。
作者简介：邢文静（1986-），女，本科，主管检验师，研究方向： 检验医学，E-mail：plr354174@21cn.com。
通讯作者：卢相琴（1981-），女，本科，主管检验师，研究方向： 检验医学。
更新日期/Last Update: 1900-01-01